TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer a

Statistically significant survival improvements in a targeted lung cancer population post-TAGRISSO progression.